Clenbuterol
Also known as: Clen, Spiropent
Beta-2 Agonist | Thermogenic Fat Loss
Overview
Clenbuterol is a potent, long-acting beta-2 adrenergic receptor agonist originally developed for the treatment of asthma and other respiratory conditions. It is approved as a bronchodilator in many countries throughout Europe, Latin America, and Asia, but has never been approved for human use in the United States, where it is only approved for veterinary use in horses (Ventipulmin). In the context of bodybuilding and physique sports, clenbuterol is widely used as a thermogenic agent during cutting phases to accelerate fat loss while preserving lean muscle mass. Its stimulatory effects on the sympathetic nervous system increase basal metabolic rate, core body temperature, and lipolysis. Unlike anabolic steroids, clenbuterol does not directly promote muscle growth in humans at typical doses, though animal studies have demonstrated significant anabolic effects in livestock, which led to its controversial use in meat production in some countries.
Key benefits
- Increased basal metabolic rate and thermogenesis for accelerated fat loss
- Preferential mobilization of stored body fat through enhanced lipolysis
- Anti-catabolic effects that help preserve lean muscle mass during caloric restriction
- Bronchodilation and improved respiratory capacity during intense exercise
- Appetite suppression in many users, supporting adherence to caloric deficit
- Oral administration with no injections required
Mechanism of action
Clenbuterol selectively binds to beta-2 adrenergic receptors on cell surfaces, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) in adipose tissue, directly stimulating lipolysis and the release of free fatty acids for oxidation. In smooth muscle tissue, beta-2 activation causes relaxation of bronchial airways, which accounts for its therapeutic use in asthma. Clenbuterol also stimulates mitochondrial uncoupling and increases thermogenesis, raising basal metabolic rate by an estimated 5-10%. Additionally, clenbuterol has mild anti-catabolic properties in humans, potentially reducing muscle protein breakdown during caloric restriction through beta-2 receptor-mediated inhibition of the ubiquitin-proteasome pathway. A significant limitation is the downregulation of beta-2 receptors with continuous use, typically occurring within 2-3 weeks, which diminishes the thermogenic effect and necessitates cycling protocols or co-administration of ketotifen (an antihistamine that upregulates beta receptors).
Molecular data
- Type
- Sympathomimetic amine (C12H18Cl2N2O)
- Half-life
- ~36 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Fat Loss / Body Composition
Cutting Phase Fat Loss
EffectiveAccelerates fat loss during caloric restriction by increasing metabolic rate and stimulating lipolysis. Most commonly used in the final weeks of a cutting phase when body fat is already relatively low and progress has stalled.
Muscle Preservation During Deficit
ModerateAnti-catabolic properties help reduce muscle protein breakdown during aggressive caloric deficits. Effect is modest in humans compared to the dramatic anti-catabolic effects observed in animal studies.
Contest Preparation
EffectiveWidely used in bodybuilding and physique competition preparation to achieve very low body fat levels. Typically deployed in the final 4-8 weeks before competition alongside other compounds.
Respiratory
Asthma / Bronchospasm
Most effectiveApproved in many countries (not the US) as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease. Relaxes bronchial smooth muscle and improves airflow.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Oral
Clenbuterol is administered orally in tablet form, typically available in 20 mcg or 40 mcg tablets. It is rapidly absorbed from the gastrointestinal tract with high oral bioavailability (~70-80%). Peak plasma concentrations are reached within 2-3 hours of ingestion. The long half-life of approximately 36 hours means that once-daily dosing is sufficient, though some users split the dose to reduce peak-related side effects. Morning administration is strongly recommended to minimize insomnia.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Standard Cutting - 2 Weeks On / 2 Weeks Off Start at 20 mcg/day and increase by 20 mcg every 1-2 days until reaching 80-120 mcg/day (dose ceiling varies by individual tolerance). Run for 14 days, then discontinue for 14 days to allow beta-2 receptor upregulation. Repeat as needed. | 20 mcg/day ramping to 80-120 mcg/day | Once daily (morning) | Oral |
| Continuous Protocol with Ketotifen Same ramping protocol as above, but ketotifen (1-2 mg before bed) is added starting at week 2 and continued throughout to prevent beta-2 receptor downregulation. Allows continuous use for 6-8 weeks without loss of efficacy. | 20 mcg/day ramping to 80-120 mcg/day | Once daily (morning) | Oral |
| Conservative / Female Protocol Lower dose ceiling appropriate for women or those with higher sensitivity to stimulants. Start at 20 mcg/day and increase by 10-20 mcg every 2-3 days. Maximum dose of 80 mcg/day for women. | 20 mcg/day ramping to 40-80 mcg/day | Once daily (morning) | Oral |
Protocol variations
Alternative cycling patterns reported in the literature and community.
2 Weeks On / 2 Weeks Off
The most widely used clenbuterol protocol. Users ramp the dose up over the first few days, maintain the peak dose for the remainder of two weeks, then discontinue completely for two weeks to allow beta-2 receptors to resensitize. During off weeks, some users substitute ephedrine/caffeine as an alternative thermogenic. This cycle is repeated for the duration of the cutting phase.
Continuous with Ketotifen
Ketotifen is an antihistamine (H1 receptor antagonist) that has been shown to upregulate beta-2 adrenergic receptors. By adding ketotifen at 1-2 mg nightly starting in the second week, users can extend clenbuterol cycles to 6-8 weeks continuously. This avoids the off periods of the traditional protocol and may produce more consistent fat loss over the cycle duration. The main drawback is that ketotifen causes drowsiness and increased appetite in some users.
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Anabolic Steroids
CompatibleFrequently combined during cutting cycles. Anabolic steroids provide muscle preservation and anabolic drive while clenbuterol accelerates fat loss. No direct pharmacological interaction, though the combination increases overall cardiovascular strain.
T3 (Liothyronine)
SynergisticT3 and clenbuterol are commonly stacked for aggressive fat loss. T3 increases basal metabolic rate through thyroid-mediated pathways while clenbuterol provides adrenergic-driven thermogenesis. However, the combination significantly increases cardiac workload, heart rate, and risk of arrhythmia. T3 is also catabolic to muscle tissue, so anabolic support is typically recommended when combining these agents.
Taurine
CompatibleClenbuterol depletes intracellular taurine levels, which is the primary cause of the muscle cramps commonly experienced during use. Supplementing with 3-5 grams of taurine daily significantly reduces or eliminates cramping. Considered a standard ancillary supplement during any clenbuterol cycle.
Ketotifen
SynergisticKetotifen (1-2 mg nightly) upregulates beta-2 adrenergic receptors, preventing the desensitization that limits clenbuterol efficacy after 2-3 weeks of continuous use. This allows extended clenbuterol cycles of 6-8 weeks. Ketotifen also has mild antihistamine sedative properties that can offset clenbuterol-induced insomnia.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Day 1-2
Onset of stimulant effects: mild tremors (especially in the hands), slight increase in heart rate, and a noticeable rise in body temperature. Appetite suppression may begin. Some users experience restlessness or difficulty sleeping.
- Day 3-5
Tremors typically peak and then begin to subside as the body adjusts. Thermogenic effect is at full strength. Increased sweating during exercise becomes apparent. Heart rate elevation stabilizes. Most users notice improved workout intensity and endurance.
- Day 6-14
Tremors largely resolve in most users. Fat loss becomes noticeable, particularly in individuals already at moderate body fat levels. Muscle cramps may begin (taurine supplementation recommended). Insomnia persists in some users. Cardiovascular endurance may be slightly impaired due to elevated resting heart rate.
- Week 3-4 (if continuing with ketotifen)
Without ketotifen, thermogenic effect diminishes noticeably by this point due to beta-2 receptor downregulation. With ketotifen, effects remain consistent. Cumulative fat loss becomes clearly visible. Muscle cramps may worsen without adequate taurine and electrolyte supplementation.
- Post-cycle
Stimulant effects wear off within 2-4 days of cessation due to the long half-life. Metabolic rate returns to baseline within 1-2 weeks. No PCT is required as clenbuterol does not affect the hormonal axis. Some users report mild lethargy and increased appetite in the first few days after stopping.
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Tremors and shaking (especially hands) - most pronounced in the first 3-5 days
- Tachycardia (elevated heart rate, typically 10-20 bpm above baseline)
- Insomnia and sleep disturbance, particularly with afternoon or evening dosing
- Muscle cramps (calves, forearms, back) due to taurine depletion
- Increased sweating and elevated body temperature
- Headaches, particularly during dose ramp-up
- Nervousness, anxiety, and restlessness
- Increased blood pressure
Rare side effects
- Cardiac hypertrophy (enlargement of the heart muscle) with chronic or high-dose use
- Cardiac arrhythmias including atrial fibrillation and ventricular tachycardia
- Severe hypokalemia (potassium depletion) leading to dangerous cardiac rhythm disturbances
- Myocardial ischemia in individuals with pre-existing cardiovascular disease
- Rhabdomyolysis (muscle breakdown) at very high doses or in combination with intense exercise
Stop signs — stop and seek advice
- Irregular or rapid heartbeat, palpitations, or chest pain
- Severe difficulty breathing or shortness of breath at rest
- Persistent nausea, vomiting, or feeling of impending doom
- Severe, unrelenting muscle cramps unresponsive to supplementation
- Dizziness, fainting, or near-syncope
- Signs of allergic reaction: rash, swelling, difficulty swallowing
Contraindications
- Pre-existing cardiovascular disease, cardiomyopathy, or arrhythmia
- Uncontrolled hypertension
- Hyperthyroidism or thyrotoxicosis
- Hypokalemia or electrolyte imbalances
- Known hypersensitivity to clenbuterol or sympathomimetic amines
- Concurrent use of other stimulants (ephedrine, amphetamines) or MAO inhibitors
- Pregnancy or breastfeeding
Monitoring
- Resting heart rate: daily (keep below 100 bpm; reduce dose if consistently elevated above baseline by more than 20 bpm)
- Blood pressure: at least weekly during use
- Serum potassium and taurine status: baseline and mid-cycle if available
- Electrocardiogram (ECG): recommended at baseline for individuals over 40 or with cardiac risk factors
- Body temperature: first few days to confirm thermogenic response (expect 0.5-1.0F increase)
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Pharmaceutical-grade tablets from a licensed manufacturer (e.g., Sopharma Clenbuterol 0.02 mg)
- Consistent tablet weight, coloring, and markings indicating quality manufacturing standards
- Proper blister packaging with lot number, expiration date, and manufacturer information
- Purchased from a licensed pharmacy with valid prescription (where approved for human use)
Warning signs
- Research chemical liquid formulations with unverified concentrations
- Tablets without pharmaceutical-grade markings or from unknown manufacturers
- Products marketed at unusual dosages (e.g., 200 mcg tablets) not consistent with standard formulations
Stop signs — don't use
- Unlabeled or improperly labeled tablets with no manufacturer identification
- Liquid preparations with visible particles, unusual color, or inconsistent dosing
- Product sourced with no third-party testing or certificate of analysis
- Any product causing effects dramatically inconsistent with expected dose-response
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
2021 · Clinical Toxicology
Clenbuterol-induced cardiac toxicity: a systematic review of case reports
Systematic review of reported cardiac adverse events associated with clenbuterol use, identifying myocardial infarction, cardiac arrhythmias, and cardiomyopathy as the most serious complications, predominantly in the context of bodybuilding use at supraphysiological doses.
2019 · British Journal of Pharmacology
Beta-2 receptor downregulation and recovery kinetics with chronic clenbuterol administration
Investigation into the time course and degree of beta-2 receptor desensitization during continuous clenbuterol administration, supporting the empirical practice of 2-week cycling protocols and quantifying receptor recovery timelines.
References
Primary literature and clinical-trial data informing this entry.
Clenbuterol: a beta-2-agonist with unusual effects on thermogenesis
Stock, M.J., Rothwell, N.J. · International Journal of Obesity · 1987
Early characterization of clenbuterol's thermogenic properties demonstrating significant increases in metabolic rate and thermogenesis in animal models, establishing the pharmacological basis for its use as a fat loss agent.
Clenbuterol in asthma. Preliminary report of a new, orally effective, selective beta-2 adrenostimulant
Anderson, G.P. · Drugs · 1993
Comprehensive review of clenbuterol's pharmacology, pharmacokinetics, and clinical use as a bronchodilator. Established the oral bioavailability, half-life (~36 hours), and therapeutic dosing range for respiratory indications.
Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation
Hoffman, R.J., Hoffman, R.S., Freyberg, C.L., et al. · Journal of Toxicology - Clinical Toxicology · 2001
Case report documenting serious cardiac arrhythmias following clenbuterol overdose, including supraventricular tachycardia and atrial fibrillation. Highlights the cardiovascular risks of clenbuterol misuse and the importance of dose limitation.
Beta-2 agonists and their effects on body composition and protein synthesis
Choo, J.J., Horan, M.A., Little, R.A., Rothwell, N.J. · Clinical Science · 1992
Demonstrated that clenbuterol increases lean body mass and decreases fat mass through beta-2 receptor-mediated pathways. Showed dose-dependent effects on protein synthesis and muscle fiber composition in animal models.
Clenbuterol residues in food producing animals: a toxicological and public health concern
Barbosa, J., Cruz, C., Martins, J., et al. · Food and Chemical Toxicology · 2005
Review of clenbuterol contamination in the food supply from its illicit use in livestock repartitioning. Documented cases of food poisoning outbreaks and established the basis for regulatory bans on clenbuterol in animal husbandry across the EU and many other jurisdictions.
Last updated . How this page was sourced is described in the methodology.